Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (The FASE Study)

详细信息	查看全文 | 推荐本文 |

• 作者：Joseph Monsonego^a ; ^{jmonsonego@wanadoo.fr} ; Michael G. Hudgens^b ; Laurent Zerat^c ; Jean-Claude Zerat^c ; Kari Syrjä ; nen^d ; Jennifer S. Smith^e
• 关键词：Cervical cancer screening ; HPV RNA test ; HPV DNA test ; CIN gold standards ; Absolute risk ; Relative risk
• 刊名：Gynecologic Oncology
• 出版年：2012
• 期刊代码：295_00908258
• 类别：med
• 出版时间：April, 2012
• 卷：125
• 期：1
• 页码：175-180
• 文件大小：184 K

摘要

Objective

New commercial HPV RNA assays require further validation studies in population-based cervical cancer screening settings.

To assess the performance of (FDA-approved) APTIMA庐 HPV Assay (AHPV), Hybrid Capture 2 (HC2), in-house PCR genotyping, and ThinPrep LBC in population-based screening, stratified by three histological gold standards.

Study design

A multi-center trial in 5006 women undergoing routine screening in France was designed to compare the absolute and relative risks of diagnosing CIN3 + and CIN2 + lesions by different diagnostic tests.

Results

Reproducibility between the primary and second pathology reading was excellent for CIN3 + and CIN2 + endpoints (Cohen's kappa 0.948 and 0.854). Absolute risks (PPV) of different tests (AHPV, HC2, PCR genotyping, LBC) in diagnosing CIN2 + (15-20%) and CIN3 + (4-6%) were similar for the first, second, and consensus pathology readings. The relative risks of diagnosing these lesions by the four tests were also similar when the first, second or third pathology readings were employed. AHPV had the highest absolute risk of both histological endpoints, and detects 5%to 15%more CIN3 + and CIN2 + lesions, respectively, than LBC. Compared with HC2 assay, the relative risk of AHPV is 24%to 29%higher, with a significant difference in CIN2 + detection. With LBC as reference, AHPV had the best sensitivity/specificity balance measured by AUC (area under ROC curve) comparison test (significant for CIN2 +), and the colposcopy referral rate (9.2%) comparable to that of LBC (8.7%).

Conclusions

These data corroborate the suitability of AHPV for the primary cervical cancer screening.